Compare IDEXX Laboratories, Inc. (IDXX) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs S&P Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while S&P Global Inc trades at $431.29 (market cap $132.71B). The key difference: S&P Global Inc is far larger — about 3× IDEXX Laboratories, Inc.'s market cap, and S&P Global Inc pays a 0.87% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | SPGI | |
|---|---|---|
Market Cap | $44.48B | $132.71B |
Sector | Health | Financials |
52-Week High | $766.68 | $534.79 |
52-Week Low | $520.87 | $370.42 |
Enterprise Value | $45.38B | $144.68B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
S&P Global (SPGI) trades at $431.26, down 4.34% on the day, amid a generally bullish technical setup with strong analyst support. The company reported robust fundamentals with 2025 revenue of $15.34B and net income of $4.47B, yielding a 30.36% net margin. Recent corporate developments include the spin-off of its mobility business and new product launches in digital asset indexing and ETF analytics, signaling strategic focus and innovation.
The outlook remains positive given strong profitability, recurring revenue model, and Wall Street's consensus price target of $532.10, implying significant upside. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Earnings growth and AI-driven data demand present the primary catalysts for shareholder value appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
